There is currently a global pandemic of obesity and diabetes.
came at the expense of significant weight gain.
Although currently available medications are effective in managing the symptoms of hyperglycemia, they do not normalize glucose metabolism nor completely eliminate the risk of long-term complications, which remain the major concern for physicians and patients alike. The UKPDS study showed that more intensive treatment with a sulfonylurea or insulin resulted in a 12% reduction (p=0.029) in any diabetes-related end-point and a significant reduction of 25% (p=0.0099) in the risk of microvascular disease compared with conventional therapy.
3 There were also clinically relevant post-trial risk reductions emerging over time for myocardial infarction (15%, p=0.01) and death from any cause (13%, p=0.007). 7 The adverse events of hypoglycemia and weight gain were, however, more frequently observed compared with conventional therapy.
Lifestyle Management of Type 2 Diabetes
Modification of lifestyle is an important factor in the management of type 2 diabetes. Proper management of smoking, physical inactivity and inappropriate diet are essential for improved glycemic control and the prevention of macrovascular disease. 8 Long-term microvascular complications may also be adversely affected by smoking. 9 International guidelines all emphasize the importance of lifestyle changes and collectively state that people with newly-diagnosed type 2 diabetes should be assessed by a dietician and given advice on an appropriate diet. It is also recommended that patients are offered interventions to encourage smoking cessation and that patients with comorbid depression are appropriately managed.
In addition to the above, patients require education on self-management, increased physical activity, smoking cessation and regular monitoring, with specific goals to improve adherence. Structured education programs are associated with improved psychological well-being, reduced anxiety and overall improvement in quality of life, 10,11 but show modest effects on HbA 1c improvement, usually in the range of 0.3-1.0%
(3-11mmol/mol). 12 For patients with type 2 diabetes, a meta-analysis of 22 studies demonstrated a mean weight loss of 3.1% (1.7kg or 3.7lbs)
from baseline body weight with lifestyle intervention. 13 Supervised exercise programs lasting from eight weeks to one year are effective for improving glycemic control and cardiovascular risk factors in people with type 2 diabetes. 14 These programs have been shown to decrease HbA 1c levels by 0.6% (7mmol/mol; p<0.05).
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Established Therapies for Type 2 Diabetes
Metformin is now established as the first-line therapy for type 2 diabetes. 
New Antihyperglycemic Therapies
Glucagon-like Peptide-1-based Therapies p<0.0001) when added to oral glucose-lowering agents. 50 Liraglutide reduced mean fasting plasma glucose more than exenatide, but post-prandial glucose increments were reduced more by exenatide than by liraglutide after breakfast and dinner. Reductions in body weight were similar in the two groups (~3kg).
Overall, GLP-1 receptor agonists have been shown to be well tolerated, with nausea and vomiting the most frequently observed adverse events.
These adverse events are dose-dependent and decline over time. 39, 40, 51 Severe hypoglycemia was rare and occurred only when sulphonylureas were co-administered. 49 There was a high incidence of development of antibodies to exenatide (up to 67% of patients) during the initial 30 weeks of treatment. 48 Some data suggest that liraglutide appears to have a lower immunogenicity than exenatide.
42-46
However, a retrospective analysis found that in patients who developed antibodies to exenatide, the titers peaked early in treatment and declined thereafter, and were not predictive of safety and efficacy. 52 A pooled analysis of four phase III studies of liraglutide found the prevalence of anti-liraglutide antibodies was <10%, although it should be noted that serum samples were taken off drug treatment. Currently, there are no long-term outcome studies but the effects on glycemic control, weight, and beta-cell function are promising.
However, further trials are needed to prove conclusively that these treatments will reduce long-term complications. 
Bromocriptine
Bromocriptine is an ergot alkaloid dopamine D 2 receptor agonist that has been used extensively in the past to treat hyperprolactinemia, galactorrhea and parkinsonism. A new, quick-release formulation has recently been approved in the US for the treatment of type 2 diabetes.
Bromocriptine-QR (administered once-daily, in the morning) appears to act centrally to the reset circadian rhythms of hypothalamic dopamine and serotonin and to improve insulin resistance and other metabolic abnormalities. 76 Clinical studies show that bromocriptine-QR lowers HbA 1c by 0.6-1.2% (7-13mmol/mol), either as monotherapy or in combination with other antidiabetes medications. 76 Apart from nausea, the drug is well tolerated.
The Role of New Anti-hyperglycemic Therapies in Type 2 Diabetes Management
The availability of these new agents offers the potential to enhance the effectiveness of therapeutic regimens for type 2 diabetes. Current As more evidence becomes available over the next few years, with more comparative data between agents and also between drug combinations, a reassessment of the current treatment strategies for restoration of glycemic control will be essential.
Current Guidelines and Recommendations
The American Diabetes Association
The ADA published its annual guidelines in January 2010 and covered management strategies for all aspects and complications of type 2 diabetes. 77 It included specific goals set for different groups, including hospitalized, pregnant, young and elderly patients. 77 Screening, diagnosis and the importance of multidisciplinary teams were discussed. It was recommended that screening for the long-term complications of nephropathy, retinopathy, neuropathy, dyslipidemia, hypertension and coronary heart disease be performed at an early stage and regularly thereafter. For optimal control of hyperglycemia and a reduction in the long-term complications of diabetes, the recommended target HbA 1c is <7% (53mmol/mol). This guideline did not specifically discuss therapeutic options, but metformin is the advised first-line drug of choice for the majority of patients.
The American Association of Clinical Endocrinologists
The Table 1 ). 
The National Institute for Clinical Excellence in England and Wales
HbA1c = glycated hemoglobin; GLP-1 = glucagon-like peptide-1; TZD = thiazolidinedione; DPP-4 = dipeptidyl peptidase-4; AGI = alpha-glucosidase inhibitor.
high body weight. Insulin therapy may be initiated when other measures no longer achieve adequate blood glucose control.
The NICE addendum recommended the addition of a DPP-4 inhibitor or a TZD to metformin as second-line therapy as well as sulfonylureas.
Recommended third-line therapy consisted of a combination of these three agents or the addition of a GLP-1 receptor agonist to metformin and a sulfonylurea when the level HbA 1c remains below 7.5% (59mmol/mol).
American Diabetes Association/European Association for the Study of Diabetes Consensus Algorithm
An algorithm for the treatment of type 2 diabetes was jointly published by a group of EASD and ADA members in 2009 (see Figure 1) . 81 p<0.0001) with 10mg dapagliflozin without any causing any weight gain. 83 The most important side-effect recognized to date is an increase in genitourinary infections, such as candidiasis.
There might be an increasing role for bariatric surgery, given the relationship between obesity and type 2 diabetes, particularly as lifestyle interventions and drug therapy are associated with only a modest degree of weight loss. In a large non-randomized study, morbidly obese patients underwent gastric surgery. 84 Step 1
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